The Pharma & Biotech Patent Litigation Summit, Europe 2023

Be Part of Europe’s Leading Pharmaceutical and Biotech legal Community to Define, Shape and Create Successful Patent Strategies and Mitigate Risks

Download our 2023 agenda
Amsterdam
24-25 January, 2023

“After a year of remote working and networking, meet the Pharma and Biotech Patent Litigation community Face-to-Face to build stronger relationships.”

Alistair Ren-Healey, Portfolio Director

WHY ATTEND

The European Summit on Pharma and Biotech Patent Litigation will be back in January 2023 for 3 days of practical discussion around the leading industry topics. Our internationally recognised summit will provide you with the necessary practical tools to both defend patent litigation challenges for your pharma and biotech product, whilst also maximising your litigation strategy to allow for successful IP protection.   

At this event, you will network with leading figures in the industry and gain unique insights on the latest regulatory changes and case-law updates. This makes it a must-attend event for anyone working within the life sciences IP industry. 

2023 Highlights Include:  

  • Action-packed pre-event workshop day, including UPC Mock Trial with our chair, Peter Meier Beck (UPC Advisory Committee).  
  • The impact of the SPC Referral cases and the uptake of the manufacturing waiver with Heidi Adler (Orion Corporation), James Horgan (MSD) and Robin Ellis (Reddie & Grose).
  • Transatlantic understanding of biologics patent litigation with topics such as: biosimilar launches, section 112 and sufficiency of disclosure with Julia Pike (Sandoz), Mike Cottler (Alvotech) and Robert Cerwinski (Gemini Law). 
  • Spotlight session with Willem Hoyng (UPC Advisory Committee Chairman) on the best venues for litigation at the UPC and the selection of the judges.

Life Sciences Patent Advisory Board

Author:

Dr. Leslie Fischer

Principal Patent Attorney
Sandoz

Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.

Dr. Leslie Fischer

Principal Patent Attorney
Sandoz

Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.

Author:

Christof Bull

Assistant General Patent Counsel
UCB

Christof Bull

Assistant General Patent Counsel
UCB

Author:

Karine Crepin

Global Head Vaccines Patents
GSK

Karine Crepin is the Vice President, Head of Vaccines Patents at GSK. She holds a Master Degree in Bioengineering (specialising in Biochemistry) and a PhD in molecular Biology. She is also a qualified European and Belgian Patent Attorney.

Before re-joining GSK in her current role, she worked for more than 9 years at Sanofi where she built a global team of more than 40 patent attorneys worldwide responsible for all patent matters relating to Sanofi Biologics including Vaccines and platform aspects, and before that for 15 years at GSK vaccines where she started her patent career.

Karine coordinates a large variety of patent related activities, from the protection of innovation to freedom-to-operate and post-grant administrative and judicial proceedings.

Karine Crepin

Global Head Vaccines Patents
GSK

Karine Crepin is the Vice President, Head of Vaccines Patents at GSK. She holds a Master Degree in Bioengineering (specialising in Biochemistry) and a PhD in molecular Biology. She is also a qualified European and Belgian Patent Attorney.

Before re-joining GSK in her current role, she worked for more than 9 years at Sanofi where she built a global team of more than 40 patent attorneys worldwide responsible for all patent matters relating to Sanofi Biologics including Vaccines and platform aspects, and before that for 15 years at GSK vaccines where she started her patent career.

Karine coordinates a large variety of patent related activities, from the protection of innovation to freedom-to-operate and post-grant administrative and judicial proceedings.

Author:

Fredrik Fredh

European Patent Attorney
Chr. Hansen

Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).

Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”

Fredrik Fredh

European Patent Attorney
Chr. Hansen

Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).

Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”

Author:

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.

Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.

From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.

Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.

Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.

From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.

Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).

Author:

Mathilde Rauline

Head of Greater Europe Patent Litigation
Sanofi

Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.

She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).

She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.

Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.

Mathilde Rauline

Head of Greater Europe Patent Litigation
Sanofi

Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.

She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).

She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.

Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.

Author:

Lorenz Kallenbach

Senior Corporate Patent Counsel
Merck

Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.

Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.

Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.

Lorenz Kallenbach

Senior Corporate Patent Counsel
Merck

Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.

Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.

Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.

Author:

Stephan Kutik

IP Lead for Nephrology and Orphan Drugs
Vifor Pharma

Stephan Kutik

IP Lead for Nephrology and Orphan Drugs
Vifor Pharma

Author:

Ewan Nettleton

Principal IP Counsel, Oncology Litigation
Novartis Pharma AG

Ewan Nettleton

Principal IP Counsel, Oncology Litigation
Novartis Pharma AG

Author:

Mike Cottler

Global Head of Litigation
Alvotech

Mike Cottler

Global Head of Litigation
Alvotech
150+
Attendees
30+
Leading Top Speakers
10+
Jurisdiction-specific Roundtable Discussions

Download Preview Agenda

Download the 2023 agenda of our upcoming event to get a preview of our key sessions, newly confirmed advisory board members, industry-leading partners and all the compelling facets of the programme.

 

Download our 2023 Agenda

OUR AUDIENCE

PARTNERS

Event Partners

Virtual Partner

Media Partners

Package

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Ticket price will increase in

Monday, September 5, 2022 to Friday, September 30, 2022
Tier 1 - In-House
€1299
Super Super Early Bird rate until 30th September (Standard €1699)
Exclusively for Pharma and Biotech
2 Day In-Person Conference Pass
You can add our pre-event workshop as an add-on during registration
Monday, September 5, 2022 to Friday, September 30, 2022
Tier 2 - Law Firms
€1799
SUPER Super Early Bird rate until 30th September (Standard €2499)
Exclusively for Law firms focusing on Life Sciences & Intellectual Properties Providers Pricing
2 Day In-Person Conference Pass
You can add our pre-event workshop as an add-on during registration
Tuesday, September 6, 2022 to Tuesday, January 24, 2023
Workshop Options
€400
Three Workshop Options to Select From
Buy 2 Get 1 Free for €800
Preparing registration...

Speakers

 

Takanori ABE

Managing Partner
ABE & PARTNERS

Mr. ABE is an Attorney-at-Law, admitted in both Japan and New York. He is currently a Guest Professor of Osaka University Graduate School of Medicine and formerly a lecturer of The University of Tokyo Graduate School of Medicine and Faculty of Medicine.  He is an arbitrator in Japan and sit on various positions in Japanese medical/pharmaceutical societies.

Takanori ABE

Managing Partner
ABE & PARTNERS

Takanori ABE

Managing Partner
ABE & PARTNERS

Mr. ABE is an Attorney-at-Law, admitted in both Japan and New York. He is currently a Guest Professor of Osaka University Graduate School of Medicine and formerly a lecturer of The University of Tokyo Graduate School of Medicine and Faculty of Medicine.  He is an arbitrator in Japan and sit on various positions in Japanese medical/pharmaceutical societies.

Mr. ABE works in wide areas of international and corporate matters with a focus on intellectual property law and international commerce. The patent litigations that he has participated covers the fields of pharmaceuticals, chemistry, electronics and machinery, which involve advanced technology such as biotechnology, semiconductors, etc., and which are cross-border matters. He has extensive experience on representing and advising multinational and domestic clients in pharmaceutical industry and is currently involved in the drastic battle between brands and also the one between brands and generics. He also has experience in trademark, copyright and unfair competition litigation.

For Mr. ABE’s detail information and activities, please visit www.abe-law.com or email to: [email protected]

 

Heidi Adler

Director Intellectual Property Rights
Orion Corporation

Heidi Adler

Director Intellectual Property Rights
Orion Corporation

Heidi Adler

Director Intellectual Property Rights
Orion Corporation
 

Sean Alexander

Head of IP Strategy
Chr. Hansen

Sean Alexander is a qualified European Patent Attorney as well as a Canadian and U.S. Patent Agent. He has worked in the IP field for many years and is currently the Head of IP Strategy (H&N) for Chr. Hansen in Denmark. Prior to joining Chr. Hansen, Sean headed the IP team at Elanco Inc. based in the Netherlands and was a Partner with Gowling WLG in Canada. Sean has been recognized as one of the world's leading IP strategists by IAM Magazine and is regularly praised for his pragmatic and commercially aware approach to IP.

Sean Alexander

Head of IP Strategy
Chr. Hansen

Sean Alexander

Head of IP Strategy
Chr. Hansen

Sean Alexander is a qualified European Patent Attorney as well as a Canadian and U.S. Patent Agent. He has worked in the IP field for many years and is currently the Head of IP Strategy (H&N) for Chr. Hansen in Denmark. Prior to joining Chr. Hansen, Sean headed the IP team at Elanco Inc. based in the Netherlands and was a Partner with Gowling WLG in Canada. Sean has been recognized as one of the world's leading IP strategists by IAM Magazine and is regularly praised for his pragmatic and commercially aware approach to IP.

 

Fiona Bor

Head of IP
Mereo BioPharma

Fiona Bor

Head of IP
Mereo BioPharma

Fiona Bor

Head of IP
Mereo BioPharma
 

Robert Cerwinski

Managing Partner
Gemini Law

Rob Cerwinski, managing partner, is a seasoned patent litigator and IP strategist with 20+ years of experience at premier U.S. law firms helping international clients launch biopharma products into the highly-competitive U.S. market. Mr. Cerwinski specializes in helping companies devise cost-effective strategies to navigate the complex and intertwined legal, regulatory and financial hurdles that can delay or prevent product launch. His successes in pre-litigation strategy and in the courtroom have driven the launch of 20+ biopharma products in the U.S. and Europe. Mr.

Robert Cerwinski

Managing Partner
Gemini Law

Robert Cerwinski

Managing Partner
Gemini Law

Rob Cerwinski, managing partner, is a seasoned patent litigator and IP strategist with 20+ years of experience at premier U.S. law firms helping international clients launch biopharma products into the highly-competitive U.S. market. Mr. Cerwinski specializes in helping companies devise cost-effective strategies to navigate the complex and intertwined legal, regulatory and financial hurdles that can delay or prevent product launch. His successes in pre-litigation strategy and in the courtroom have driven the launch of 20+ biopharma products in the U.S. and Europe. Mr. Cerwinski holds a Master of Science Degree in molecular biology and has a deep understanding of the science, business and regulation of biopharma product development, manufacture and marketing. Mr. Cerwinski co-founded the industry-leading biosimilars practice at Goodwin Procter LLP and is a recognized global authority on biosimilars. He is Senior Editor of the leading legal treatise in the field, Guide to Biosimilars Litigation and Regulation in the U.S. (published by Thomson-Reuters) and founded Goodwin’s award-winning biosimilars blog, Big Molecule Watch and its companion blog, Big Molecule Watch China. Mr. Cerwinski was named an IAM Global Leader in Intellectual Property Law in 2021 and is ranked in the Gold Tier of the IAM Patent 1000. 

 

Mike Cottler

Global Head of Litigation
Alvotech

Mike Cottler

Global Head of Litigation
Alvotech

Mike Cottler

Global Head of Litigation
Alvotech
 

Jenny Davies

Partner
Gowling

Jenny Davies

Partner
Gowling

Jenny Davies

Partner
Gowling
 

Robin Ellis

Partner
Reddie&Grose

Robin Ellis

Partner
Reddie&Grose

Robin Ellis

Partner
Reddie&Grose
 

Christopher Freeth

Principal Associate
Gowling WLG

Christopher Freeth

Principal Associate
Gowling WLG

Christopher Freeth

Principal Associate
Gowling WLG
 

Michael Frohlich

Director European and International Legal Affairs
EPO

Michael Frohlich

Director European and International Legal Affairs
EPO

Michael Frohlich

Director European and International Legal Affairs
EPO
 

Gerben Hartman

Lawyer
CJEU

Gerben Hartman is a lawyer in the Research and Documentation directorate of the Court of Justice of the European Union (CJEU) since 2021, where he carries out preliminary analyses of references for a preliminary ruling and other case-related research. His work mainly focuses on all areas of Intellectual Property law. Previously (2010-2016), he worked as a lawyer at a top-tier law firm in the Netherlands.

Gerben Hartman

Lawyer
CJEU

Gerben Hartman

Lawyer
CJEU

Gerben Hartman is a lawyer in the Research and Documentation directorate of the Court of Justice of the European Union (CJEU) since 2021, where he carries out preliminary analyses of references for a preliminary ruling and other case-related research. His work mainly focuses on all areas of Intellectual Property law. Previously (2010-2016), he worked as a lawyer at a top-tier law firm in the Netherlands. He completed his law studies at the university of Nijmegen (2009) and Stanford Law School (2017), followed by a four-year EU Marie Skłodowska-Curie fellowship at Queen Mary University of London, with secondments in the Legal Service of the European Union Intellectual Property Office (EUIPO) and in the cabinet of Judge Niilo Jääskinen at the CJEU.

 

James Horgan

Assistant Managing Counsel
MSD

James Horgan

Assistant Managing Counsel
MSD

James Horgan

Assistant Managing Counsel
MSD
 

Willem Hoyng

Chairman
UPC Advisory Committee

Willem Hoyng

Chairman
UPC Advisory Committee

Willem Hoyng

Chairman
UPC Advisory Committee
 

Paul Inman

Partner
Gowling

With 20 years' experience of litigating intellectual property disputes both within the UK and internationally, Paul Inman works with companies ranging from small start-ups to major multi-national corporations. He specialises in the life sciences sector, which has included acting on high-profile pharmaceutical patent infringement and revocation actions in the UK Patents Court.

Paul Inman

Partner
Gowling

Paul Inman

Partner
Gowling

With 20 years' experience of litigating intellectual property disputes both within the UK and internationally, Paul Inman works with companies ranging from small start-ups to major multi-national corporations. He specialises in the life sciences sector, which has included acting on high-profile pharmaceutical patent infringement and revocation actions in the UK Patents Court.

As a global industry, life science businesses expect commercial advice from lawyers with an international outlook. Paul's specialist experience and skill set make him perfectly placed to provide this expertise and client care.

His role has extended to litigating across industries as diverse as fashion, oil drilling and consumer products both here, and overseas.

Whether "success" is measured by getting the right court order at the end of the dispute, or evaluating and reaching the right commercial settlement between the parties beforehand, a thorough and balanced assessment on each case is critical. The ultimate aim for Paul is to provide his clients with well-rounded advice and guidance to ensure the best possible outcome.

His interest and expertise in the life sciences sector has also seen him advising on regulatory work concerning European pharmaceutical bodies.

Paul's role gives him the unique opportunity to act for a wide range of patent and design proprietors, which he relishes.

Paul's first degree is in molecular biology and biochemistry, which means he can take on highly complex pharmaceutical or biotechnology inventions, as easily as less technical (but equally important) mechanical patents and designs.

Successfully guiding clients through the maze of litigation is where Paul's strength lies, having now been involved over 20 years of litigation in cases leading to more than 40 reported judgments, ranging from the tribunals of the UK Patent Office (UKIPO) up to the House of Lords (UK Supreme Court), European Patent Office (EPO) and European Court of Justice (CJ EU).

As well as litigating in the English courts, Paul has co-ordinated and advised on IP and regulatory litigation matters across the globe, as far afield as the US, South Africa, Malaysia, the Philippines, Australia and New Zealand, and closer to home, in Scotland, Ireland, France, Germany, Holland, Denmark, Belgium, Spain, Portugal, Italy and Greece.

It is this great variety of work and clients that, for Paul, really makes the job dynamic and exciting, week-in and week-out.

 

Stephan Kutik

IP Lead for Nephrology and Orphan Drugs
Vifor Pharma

Stephan Kutik

IP Lead for Nephrology and Orphan Drugs
Vifor Pharma

Stephan Kutik

IP Lead for Nephrology and Orphan Drugs
Vifor Pharma
 

Peter Meier-Beck

Presiding Judge (Ret.) and German Member of the
UPC Advisory Committee

Peter Meier-Beck is a retired Presiding Judge of the Bundesgerichtshof, the German Federal Supreme Court.

After serving as a judge at the Regional Court and the Higher Regional Court of Düsseldorf from 1985 to 2000, Peter Meier-Beck was appointed as a Federal Judge. From 2010 to 2019, he chaired the 10th Civil Senate, i.e. the Patent Division, as Presiding Judge, and from 2019 until his retirement from office at the end of September 2021, he headed the Cartel (Antitrust) Senate.

Peter Meier-Beck

Presiding Judge (Ret.) and German Member of the
UPC Advisory Committee

Peter Meier-Beck

Presiding Judge (Ret.) and German Member of the
UPC Advisory Committee

Peter Meier-Beck is a retired Presiding Judge of the Bundesgerichtshof, the German Federal Supreme Court.

After serving as a judge at the Regional Court and the Higher Regional Court of Düsseldorf from 1985 to 2000, Peter Meier-Beck was appointed as a Federal Judge. From 2010 to 2019, he chaired the 10th Civil Senate, i.e. the Patent Division, as Presiding Judge, and from 2019 until his retirement from office at the end of September 2021, he headed the Cartel (Antitrust) Senate.

Peter Meier-Beck has taught patent law since 1995. In 2005, he was appointed honorary professor by Heinrich Heine University Düsseldorf and in 2022 by University College London.

 

Wolf Meier-Ewart

Counsellor- Secretary of the Council for TRIPS, WTO Intellectual Property
Government Procurement and Competition Division

Wolf Meier-Ewart

Counsellor- Secretary of the Council for TRIPS, WTO Intellectual Property
Government Procurement and Competition Division

Wolf Meier-Ewart

Counsellor- Secretary of the Council for TRIPS, WTO Intellectual Property
Government Procurement and Competition Division
 

Ewan Nettleton

Principal IP Counsel, Oncology Litigation
Novartis Pharma AG

Ewan Nettleton

Principal IP Counsel, Oncology Litigation
Novartis Pharma AG

Ewan Nettleton

Principal IP Counsel, Oncology Litigation
Novartis Pharma AG
 

Julia Pike

Global Head of IP
Sandoz

Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.

 

Julia Pike

Global Head of IP
Sandoz

Julia Pike

Global Head of IP
Sandoz

Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.

 

Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world. 

 

Adrian Spillmann

Director of Intellectual Property
Valneva

Adrian Spillmann is Director of Corporate Intellectual Property for the Valneva group (a European biotech company focusing on vaccines) in Vienna, Austria, and specializes in patent and trademark prosecution, patent and trademark enforcement, patent drafting, patent portfolio management, in house patent counseling, patent monetization and intellectual property transactions in biotechnology and pharmaceuticals and other life science projects.

Adrian Spillmann

Director of Intellectual Property
Valneva

Adrian Spillmann

Director of Intellectual Property
Valneva

Adrian Spillmann is Director of Corporate Intellectual Property for the Valneva group (a European biotech company focusing on vaccines) in Vienna, Austria, and specializes in patent and trademark prosecution, patent and trademark enforcement, patent drafting, patent portfolio management, in house patent counseling, patent monetization and intellectual property transactions in biotechnology and pharmaceuticals and other life science projects.

His areas of expertise include protection of prophylactics, therapeutics, and diagnostics for infectious diseases, immunological disorders, cancerous diseases, neurodegenerative disorders and metabolic disorders, vaccine technologies, antibody technologies, production of biological and chemical compounds, new medical uses, and formulations of known compounds.

After earning his Ph.D. at the University of Zurich, Switzerland, Adrian was a Consultant at Deloitte, followed by a 7-year stay in various positions in the patent department at Novartis. Furthermore, Adrian was Senior Patent Attorney at Ablynx, an antibody company in Belgium, for three years.

Adrian is a European and Swiss-registered patent attorney and received his LLM from the University of Law in London.

 

Corinna Sundermann

Senior Vice President Intellectual Property
bei Fresenius Kabi Deutschland GmbH

Corinna Sundermann has been heading the IP department of the Pharma Division at Fresenius Kabi. She joined Fresenius Kabi in 2008 as a Manager and built the IP department from 1 to 30 FTE since then. She has been the Senior Vice President since 2012. Her focus is on generics, branded products, clinical nutrition and medical devices. Before joining Fresenius Kabi, she worked 10 years for an originator company, 5 years as a Head of Combinatorial Chemistry, 5 years in the IP department and has been a European Patent Attorney since 2006. She holds a Dr. rer. nat.

Corinna Sundermann

Senior Vice President Intellectual Property
bei Fresenius Kabi Deutschland GmbH

Corinna Sundermann

Senior Vice President Intellectual Property
bei Fresenius Kabi Deutschland GmbH

Corinna Sundermann has been heading the IP department of the Pharma Division at Fresenius Kabi. She joined Fresenius Kabi in 2008 as a Manager and built the IP department from 1 to 30 FTE since then. She has been the Senior Vice President since 2012. Her focus is on generics, branded products, clinical nutrition and medical devices. Before joining Fresenius Kabi, she worked 10 years for an originator company, 5 years as a Head of Combinatorial Chemistry, 5 years in the IP department and has been a European Patent Attorney since 2006. She holds a Dr. rer. nat. from the University of Jena and a diploma in chemistry from the University of Frankfurt.

Partner With Us

Based on your objectives, we can create bespoke packages designed specifically for you – from presenting your expertise on the main stage, to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

To discuss your objectives and partnership opportunities please contact [email protected]

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]

Resources

Download Resource

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us